Wordt geladen...
Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer
QUESTION: What are the benefits associated with the use of anti–epidermal growth factor receptor (anti-egfr) therapies in squamous cell carcinoma of the head and neck (hnscc)? Anti-egfr therapies of interest included cetuximab, gefitinib, lapatinib, zalutumumab, erlotinib, and panitumumab. PERSPECTI...
Bewaard in:
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Multimed Inc.
2010
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2880902/ https://ncbi.nlm.nih.gov/pubmed/20567625 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|